For the interim period of the fiscal year ending March 2027, consolidated results were: net sales 49,198.1 million yen, operating loss 331,127 thousand yen, ordinary loss 294,611 thousand yen, and net loss attributable to owners of parent 295,444 thousand yen. The new consolidated subsidiary MediProduce Co., Ltd. was acquired in July 2026, and segment reporting was changed to three segments: R&D, PCO, and HC. The full-year earnings forecast has been revised and disclosed. Cash was 1,186,852 thousand yen, total assets 1,463,230 thousand yen, and equity ratio 42.3%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4890","jir_company_name":"Tsubota Laboratory Incorporated","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4890-20261111-01.pdf","jir_short_summary":"For the interim period of the fiscal year ending March 2027, consolidated results were: net sales 49,198.1 million yen, operating loss 331,127 thousand yen, ordinary loss 294,611 thousand yen, and net loss attributable to owners of parent 295,444 thousand yen. The new consolidated subsidiary MediProduce Co., Ltd. was acquired in July 2026, and segment reporting was changed to three segments: R&D, PCO, and HC. The full-year earnings forecast has been revised and disclosed. Cash was 1,186,852 thousand yen, total assets 1,463,230 thousand yen, and equity ratio 42.3%.","jir_summary":"### Overview of Performance\nThe Company made MediProduce Co., Ltd. a consolidated subsidiary in July 2026 and has prepared consolidated interim financial statements from this interim period. For the interim period of the fiscal year ending March 2027, consolidated net sales were 491,981 thousand yen, operating loss was 331,127 thousand yen, ordinary loss was 294,611 thousand yen, and net loss attributable to owners of parent was 295,444 thousand yen. Sales increased due to contributions from the newly consolidated subsidiary; however, expenses such as research and development and promotional costs were heavy, resulting in a recorded deficit. The full-year earnings forecast has been revised and published, and continued promotion of licensing and new out-licensing agreements will be important.\n\n### Business Strategy and Capital Policy Trends\nThe Company reorganized into three segments: R&D, PCO, and HC. Approximately 1,990 million yen was raised through a third-party allotment of stock acquisition rights, planned to be allocated to clinical development, out-licensing investments, and the ReLight Tech business. Through the consolidation of MediProduce, the Company aims to diversify its revenue base and strengthen the funding base for growth investments.","jir_financial_highlights":"Net Sales: 491,981 thousand yen (No year-over-year comparison (transition to interim reporting))\nOperating Loss: -331,127 thousand yen (No year-over-year comparison (transition to interim reporting))\nOrdinary Loss: -294,611 thousand yen (No year-over-year comparison (transition to interim reporting))\nNet Loss Attributable to Owners of Parent (Interim): -295,444 thousand yen (No year-over-year comparison (transition to interim reporting))\nCash and Cash Equivalents: 1,186,852 thousand yen (At period end)\nEquity Ratio: 42.3% (At period end)","jir_category":"","jir_hashtags":"#TsubotaLaboratory, #Earnings, #InterimResults, #Consolidation, #ReLightTech","jir_key_figures":"Net Sales: 491,981 thousand yen\nOperating Loss: -331,127 thousand yen\nNet Loss Attributable to Owners of Parent (Interim): -295,444 thousand yen","jir_meta_title":"Tsubota Laboratory Incorporated: Financial Summary for Q2 FY2027 | Consolidation and Shift to Three-Segment Structure","jir_meta_description":"Summary of Tsubota Laboratory Incorporated's financial results for Q2 FY2027: contribution from a newly consolidated subsidiary, causes of the deficit, cash and capital position, and revision of the full-year outlook.","jir_og_title":"Tsubota Laboratory Incorporated Q2 Financial Summary | Consolidation and Three-Segment Structure","jir_og_description":"Interim results show a deficit due to contributions from a newly consolidated subsidiary and increased expenses; cash stood at 1,186 million yen. Full-year outlook has been revised.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":122803,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149195","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n